MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics today announced the Company has initiated enrollment in a second global, pivotal, Phase 3 study (DISCOVER-2) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). Durata’s two pivotal studies (DISCOVER-1 and DISCOVER-2) are being conducted under separate Special Protocol Assessments (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).
